Cocaine Abuse Clinical Trial
Official title:
Phase 1, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Potential Interactions Between Intravenous Cocaine and Oral Lorcaserin
The primary objective of this study is to determine if there are significant interactions between oral lorcaserin treatment concurrent with 20 and 40 mg intravenous (i.v.) cocaine infusions by measuring adverse events (AEs) and cardiovascular responses including heart rate (HR), blood pressure (BP), and electrocardiogram (ECG) (including QTc).
Status | Completed |
Enrollment | 20 |
Est. completion date | September 2015 |
Est. primary completion date | August 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility |
Inclusion Criteria: - Be volunteers who are not seeking treatment for drug addiction. - Be between 18 and 50 years-of-age. - Meet Diagnostic and Statistical Manual (DSM-IV) - Text Revision (TR) criteria for current cocaine abuse as assessed using the MINI neuropsychiatric interview (version 6.0). - Have a body mass index (BMI) within a range of 18.0 to 34.0 kg/m2 and a minimum weight of at least 50.0 kg at screening. - Have experience using cocaine by the smoked or i.v. route at least 6 times in the past 12 months prior to clinic intake (Day -3) and at least one use within the past 30 days. - Provide a urine sample positive for cocaine at least once during screening (Days -28 to -4). - Be able to verbalize understanding of consent form, able to provide written informed consent, and verbalize willingness to complete study procedures. - Females must have a negative serum pregnancy test at screening and negative urine pregnancy test at intake prior to receiving the first dose of investigational drug. They must also be postmenopausal, have had a hysterectomy, been sterilized, have a partner with a vasectomy, or agree to use one of the following methods of birth control starting at least 14 days prior to clinic intake: 1. diaphragm and condom by partner 2. condom and spermicide by partner 3. intrauterine device and condom by partner 4. sponge and condom by partner 5. complete abstinence from sexual intercourse 6. oral contraceptives, Depo-Provera, Norplant, Patch, and intrauterine progesterone contraceptive - Be able to comply with protocol requirements, rules and regulations of the study site and be likely to complete all the study treatments. Exclusion Criteria: - Please contact site directly for more information |
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic
Country | Name | City | State |
---|---|---|---|
United States | Vince Associates Clinical Research, Inc. | Overland Park | Kansas |
Lead Sponsor | Collaborator |
---|---|
National Institute on Drug Abuse (NIDA) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants with Adverse Events | From intake (day -3) through follow-up (day 26) | Yes | |
Primary | Number of Participants with Cardiovascular Responses | From screening (day -28 through day -4) through follow-up (day 26) | Yes | |
Secondary | Number of Participants with an Change in the Pharmacokinetics (PK) of Cocaine by Measuring the Cocaine Concentration in Plasma | Day 4, 6, 8 through 12 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01601743 -
Exercise as a Behavioral Treatment for Cocaine Dependence
|
N/A | |
Completed |
NCT00217997 -
Impulsivity, Brain Function, and Substance Abuse Treatment in Cocaine Dependent Individuals
|
N/A | |
Terminated |
NCT00142883 -
The Effects of GABA Enhancing Medications on Individuals Addicted to Cocaine - 3
|
N/A | |
Completed |
NCT00842517 -
Long Term Maintenance of Drug Abstinence
|
Phase 1 | |
Completed |
NCT00227903 -
Therapeutic Substance Abuse Treatment in Pregnancy - 1
|
Phase 2 | |
Completed |
NCT02563769 -
Clavulanic Acid (CLAV) and Cocaine Interaction Safety Study
|
Phase 1 | |
Completed |
NCT01651377 -
Pramipexole as a Treatment for Cocaine Dependence
|
Phase 1 | |
Recruiting |
NCT00439049 -
Substance Abuse Pre-Treatment Screening Study
|
||
Completed |
NCT00249457 -
Employment-based Reinforcement to Motivate Drug Abstinence in the Treatment of Drug Addiction. - 2
|
N/A | |
Completed |
NCT01401270 -
Prize Contingency Management for Cocaine-Dependent Methadone Patients
|
N/A | |
Completed |
NCT00350610 -
Computer-Based Training in Cognitive Behavior Therapy
|
Phase 1 | |
Recruiting |
NCT06177860 -
Clinical and Atherosclerotic Characteristics of Patients With ACS Associated With Cocaine Use
|
||
Completed |
NCT02141620 -
n-Acetylcysteine and Cocaine
|
Phase 0 | |
Recruiting |
NCT00218023 -
Medications for Stopping Cocaine Dependence and Preventing Relapse
|
Phase 2 | |
Completed |
NCT00218075 -
Behavioral Therapy Combined With Carbidopa/Levodopa for the Treatment of Cocaine Dependence
|
Phase 2 | |
Recruiting |
NCT05857852 -
Low-Intensity Focused Ultrasound for Cocaine Use Disorder
|
N/A | |
Completed |
NCT00606801 -
Galantamine Effects on Cognitive Function in Abstinent Cocaine Users
|
N/A | |
Completed |
NCT00292123 -
Combined Behavioral and Pharmacologic Treatment of Polydrug Abuse
|
Phase 1 | |
Completed |
NCT00318760 -
Effect of Clonidine on Responses to Imagery Scripts
|
Phase 1 | |
Completed |
NCT01651364 -
A Pilot Study of Cabergoline for the Treatment of Cocaine Dependence
|
Phase 1 |